Acute Lymphoblastic Leukemia (ALL)

First (CR1) or Higher Remission
- Match Related
- Haplo
- dUCB

First (CR1) or Second Remission (CR2)
- Autologous or Allogeneic

Advanced Disease
- Matched Related or Unrelated Donor

CCT5001
- Phase I
- CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/Refractory B Cell Malignancies
  - PI: Miklos Stanford

BMT343
- Phase Ib
- T-Cell-Depleted Graft + Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
  - PI: Meyer Orca Biosystems

BMT342
- Phase II/III to Identify Novel Intervention to Alleviate Morbidity & Mortality After Allogeneic HCT
  - PI: Johnston Fred Hutchinson

BMT372
- Phase I Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/ T-Cell Depleted Graft
  - PI: Meyer Stanford

BMT338
- Phase I
- DonorGrafts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
  - PI: Meyer Orca Biosystems

BMT369
- Phase II
- MOTA-145 in Combination with Plerixafor in Hematological Malignancies
  - PI: Meyer Orca Biosystems

BMT339
- CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ TCell Infusion in MDS/AL
  - PI: Lowsky Stanford

BMT338
- Phase I
- DonorGrafts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
  - PI: Rezvani Gamida Cell

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Enrolment on Hold
- Extension Study
- Immunotherapy

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu